US Stock Market Move | AI will be used to develop weight loss drugs, and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has increased by nearly 2% against the trend.
On Friday, Novo Nordisk (NVO.US) defied the trend and rose nearly 2%, closing at $86.77.
On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose nearly 2% against the market trend, closing at $86.77 USD. In terms of news, the company and the U.S. technology company Valo Health recently announced their agreement to expand the scope of their collaboration to develop up to 11 drugs by 2023, utilizing human data and artificial intelligence (AI) to develop up to 20 new therapies for obesity, type 2 diabetes, and cardiovascular diseases.
Related Articles
In 2025, DUALITYBIO-B(09606) achieved approximately 1.852 billion yuan in revenue, with significant progress in pipeline development and business operations.
Nations Technologies Inc. (02701) added to the "Stock Connect" securities list.
New stock news | Bao Gai New Materials' Hong Kong stock IPO has been approved by the China Securities Regulatory Commission.
In 2025, DUALITYBIO-B(09606) achieved approximately 1.852 billion yuan in revenue, with significant progress in pipeline development and business operations.
Nations Technologies Inc. (02701) added to the "Stock Connect" securities list.
New stock news | Bao Gai New Materials' Hong Kong stock IPO has been approved by the China Securities Regulatory Commission.
